Skip to Main Content

Paper Details

Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Circulation
3
2023
Dapagliflozin, HF, Heart Failure, Patient, Patients, Preserved Ejection Fraction Heart Failure, cardiovascular death, dapagliflozin, glucose, glucose cotransporter 2, heart failure, patient, patients, person, sodium
Author NameAffiliation
Rudolf A de BoerErasmus Medical Center
Akshay S DesaiBrigham and Women's Hospital, Harvard Medical School
Adrian F HernandezDuke University Medical Center
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City
Carolyn S P LamNational Heart Centre Singapore & Duke-National University of Singapore (C.S.P.L.).
  • 1 - 5

Datasets

Release 1.2